Navigation Links
Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Date:7/20/2009

AIEA, Hawaii, July 20 /PRNewswire/ -- The Centers for Disease Control and Prevention reported this week that the prevalence of obesity among Americans is now over 26%. Obesity exacerbates a constellation of diseases including diabetes, liver disease, and heart disease, often in the same patient, and is referred to as "metabolic syndrome." Low level inflammation and oxidative stress are the mechanistic underpinnings of metabolic syndrome.

The Cardax lead compound is a novel and highly bioavailable proprietary derivative of the natural dietary carotenoid astaxanthin that addresses metabolic syndrome, including liver and cardiovascular disease as well as diabetes. Preclinical animal studies with the Company's compounds or its active metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels indicative of liver damage, such as ALT and AST, are decreased, pointing to an outstanding safety profile. Increases in HDL, the "good" cholesterol and increased insulin sensitivity have also been documented along with a robust improvement in thrombosis and myocardial salvage.

The Cardax drug reduces systemic inflammation and oxidative stress while localizing in the liver and the vasculature. Cellular studies have determined that this compound acts as a plasma and mitochondrial membrane stabilizer and a potent antioxidant.

"Cardax has pioneered a novel approach to treating the source of inflammation, intracellular oxidative stress," said David G. Watumull, CEO of Cardax. "We believe this to be a new paradigm for the treatment of liver and cardiovascular disease as well as metabolic syndrome."

"Our novel derivative of the natural carotenoid astaxanthin exhibits dramatically improved bioavailability relative to the parent compound," adds Chief Medical
'/>"/>

SOURCE Cardax Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
2. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
5. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
6. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
7. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
10. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
11. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015 Actavis plc (NYSE: ... offering of $21 billion aggregate principal amount of senior ... offering to be issued by its indirect wholly-owned subsidiary, ... other subsidiaries (the "Notes"), as follows: Logo ... Notes* , $500,000,000 , Due 2016 , ...
(Date:3/3/2015)... 2015  Cumberland Pharmaceuticals Inc. (NASDAQ: ... hospital acute care and gastroenterology, today announced achievement ... include top-line results from the Company,s Hepatoren Phase ... Application (sNDA) with pediatric data for Caldolor and ... II clinical trial. "The sNDA for ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/tbjpmj/blister_packaging ) ... Market in the US 2015-2019" report to their ... the US to grow at a CAGR of 6.11% ... form of high-visibility packaging that uses pre-formed plastic packs ... a base layer, made either of plastic or aluminum, ...
Breaking Medicine Technology:Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 2Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 3Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 4Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 5Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 6Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 7Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 8Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 9Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan 10Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones 2Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones 3Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones 4Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones 5United States Blister Packaging Market 2015-2019 - Growing Demand in Pharmaceuticals Industry with Amcor, Bemis, MeadWestvaco & Sonoco Products Dominating 2
... Oct. 31, 2011 Rock Creek Pharmaceuticals, a wholly owned ... today announced the second presentation of research findings related to ... a Tobacco Alkaloid, Ameliorates Disease in a Mouse Model of ... meeting of the American Thyroid Association in Indian Wells, CA ...
... SYDNEY, Oct. 31, 2011  To successfully irradiate a moving lung ... the tumor from moving or a means to compensate for ... Hospital Cancer Centre (Randwick, New South Wales) chose the second ... for the first time to treat a 75-year-old male patient ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatabloc™ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting 2Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatabloc™ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting 3Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatabloc™ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting 4Australia's Prince of Wales Hospital Launches New Era of Targeted Lung Cancer Treatments with Elekta's Advanced 4D Motion Management Technology 2Australia's Prince of Wales Hospital Launches New Era of Targeted Lung Cancer Treatments with Elekta's Advanced 4D Motion Management Technology 3
(Date:3/4/2015)... March 04, 2015 Information Innovators ... John Dvorak has joined the company as Chief ... the technology focus for the company, including customer-centric strategies ... brings 20 years of experience as a technology executive ... diverse roles at the FBI including oversight of enterprise ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 According to ... millions of people in the U.S. suffer from gastroesophageal ... Medications are commonly prescribed to control acid production, but ... procedures can overly correct the problem and lead to ... Opportunity, GERD occurs when the lower esophageal sphincter does ...
(Date:3/4/2015)... Ohio (PRWEB) March 04, 2015 Staff ... an IED explosion in Iraq, tells you about the ... received some free Chiropractic care from the Patriot Project ... Therapy. , This is what Harris said in a ... I have clarity, I feel more calm, I'm sleeping ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Today Visiopharm ... Dako , has joined the Visiopharm Board of ... at a time when we are positioned to become ... pathology for cancer diagnostics and research. , ... in the development and validation of ONCOtopix™ Dx, a ...
(Date:3/4/2015)... 2015 Nike Swim Camps offer outstanding ... mission is to stimulate a love of swimming in ... provide campers the opportunity to train with some of ... Merrion, Vice President of US Sports Camps. “Our program ... to build confidence and improve their technique.” , Nike ...
Breaking Medicine News(10 mins):Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 3Health News:Decorated Veterans Endorse “Halos for Heroes” an Indiegogo campaign to Help Wounded Military Heal at Home 2Health News:Decorated Veterans Endorse “Halos for Heroes” an Indiegogo campaign to Help Wounded Military Heal at Home 3Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3Health News:US Sports Camps and Nike Swim Camps Announce the 2015 Swim Camps Lineup 2
... in utero stem cell treatment could lead to a ... a range of other disabling,conditions, according to a maternal-fetal ... , Action Medical Research has announced the outcomes of ... by Professor Nicholas Fisk, that could lead to a ...
... in the human genome that originated from ancient viral ... are even essential for a healthy pregnancy, according to ... , Retrovirus infections represent the most intimate host-pathogen relationship. ... the DNA of the host cell, resulting in an ...
... improves enterprise security, reduces risk and ... ... Inc., a global,provider of integrated security, risk and audit management ... Kingdom,s National,Health Service (NHS) has selected its flagship SecureVue(R) platform ...
... Home care services franchise jumps to #187 in Entrepreneur Magazine,s 29th ... ... Homewatch CareGivers has been ranked,#187 in Entrepreneur Magazine,s 29th Annual Franchise ... by 40 places,over 2007, and retained its rankings among top industry ...
... ABBOTT PARK, Ill., Jan. 29 Abbott will,present ... Device Conference on Tuesday, Feb. 5, 2008. Thomas ... officer, will make a,formal presentation on the company ... audio webcast of the presentation will be accessible ...
... a New Way to Shop for Baby Products, With Information, on ... ... Well, NORCROSS, Georgia, ... The,comprehensive website offers new parents an opportunity to save time and,money with ...
Cached Medicine News:Health News:Stem cell treatment for brittle bones in the womb 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 3Health News:Homewatch CareGivers Improves in Entrepreneur Magazine Rankings 2Health News:BabySupply.Info Announces Launch of Website for New Parents 2
LB Agar plates with 0.1mM EDTA....
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth...
Medicine Products: